Bortezomib shows promise in reducing GVHD and reconstituting immune system in some patients

(Dana-Farber Cancer Institute) A drug that has become a mainstay of multiple myeloma treatment may outperform alternative therapies in re-establishing the immune system of patients who have received stem cell transplants from unrelated, partially matched donors, according to early clinical trial results to be presented by Dana-Farber Cancer Institute investigators at the American Society of Hematology’s annual meeting on Sunday, Dec. 6.

source : www.eurekalert.org

Related News:

• Hospira Begins Phase I U.S. Clinical Trial Of Biosimilar Erythropoietin In Renal Patients
• Many Knee And Hip Replacement Patients Experience Weight Decrease After Surgery
• Helping Neurons Fix Themselves In Parkinson’s Patients
• Inflammatory Arthritis Patients Lacking in Preventive Care
• Vision Loss Halted By Valproic Acid In Patients With Retinitis Pigmentosa
• World’s Largest Study On Insulin Therapy Completes Recruitment With 60,000 Patients
• Shoulder Arthritis? What Patients Need To Know Before Treatment
• Older Patients Are Less Likely To Receive Home Treatment As New Study Reveals Significant Quality Of Life Benefits, UK
• WFH: Acupuncture Eases Pain in Hemophilia Patients
• Early Antivirals Best for H1N1 in Transplant Patients

Details :
Submited at Sunday, December 6th, 2009 at 7:00 pm on Cancer and Oncology by hilman
Comment RSS 2.0 - leave a comment - trackback